SEARCH

SEARCH BY CITATION

References

  • 1
    Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32:141-156.
  • 2
    Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol 2005;39:S125-S130.
  • 3
    Graupera M, Garcia-Pagan JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003;37:172-181.
  • 4
    Graupera M, Garcia-Pagan JC, Pares M, Abraldes JG, Rosello J, Bosch J, et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol 2003;39:515-521.
  • 5
    Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-491.
  • 6
    Loureiro-Silva MR, Cadelina GW, Groszmann RJ. Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol 2003;284:G567-G574.
  • 7
    Graupera M, March S, Engel P, Rodes J, Bosch J, Garcia-Pagan JC. Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol 2005;288:G763-G770.
  • 8
    Rosado E, Rodriguez-Vilarrupla A, Gracia-Sancho J, Monclus M, Bosch J, Garcia-Pagan JC. Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats. J Cell Mol Med 2012;16:2461-2470.
  • 9
    Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Bosch J, Garcia-Pagan JC. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 2007;47:220-227.
  • 10
    Dogne JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, et al. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 2006;12:903-923.
  • 11
    Gardi C, Arezzini B, Monaco B, De Montis MG, Vecchio D, Comporti M. F2-isoprostane receptors on hepatic stellate cells. Lab Invest 2008;88:124-131.
  • 12
    Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008;118:18-35.
  • 13
    Cimetiere B, Dubuffet T, Landras C, Descombes JJ, Simonet S, Verbeuren TJ, et al. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors. Bioorg Med Chem Lett 1998;8:1381-1386.
  • 14
    Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003;41:1198-1204.
  • 15
    Gelosa P, Ballerio R, Banfi C, Nobili E, Gianella A, Pignieri A, et al. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. J Pharmacol Exp Ther 2010;334:199-205.
  • 16
    Gelosa P, Sevin G, Pignieri A, Budelli S, Castiglioni L, Blanc-Guillemaud V, et al. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol 2011;300:H762-H768.
  • 17
    Xu S, Jiang B, Maitland KA, Bayat H, Gu J, Nadler JL, et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 2006;55:110-119.
  • 18
    Liu CQ, Leung FP, Wong SL, Wong WT, Lau CW, Lu L, et al. Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase. Biochem Pharmacol 2009;78:374-381.
  • 19
    De La Cruz JP, Jebrouni N, Lopez-Villodres JA, Munoz-Marin J, Guerrero A, Gonzalez-Correa JA. Effects of terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, on retinal vascularity in diabetic rats. Diabetes Metab Res Rev 2012;28:132-138.
  • 20
    Rodriguez-Vilarrupla A, Lavina B, Garcia-Caldero H, Russo L, Rosado E, Roglans N, et al. PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol 2012;56:1033-1039.
  • 21
    Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009;49:1245-1256.
  • 22
    Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009;27(Suppl 3):20-27.
  • 23
    Sebekova K, Eifert T, Klassen A, Heidland A, Amann K. Renal effects of S18886 (terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes. Diabetes 2007;56:968-974.
  • 24
    Valentin JP, Jover B, Maffre M, Bertolino F, Bessac AM, John GW. Losartan prevents thromboxane A2/prostanoid (TP) receptor mediated increase in microvascular permeability in the rat. Am J Hypertens 1997;10:1058-1063.
  • 25
    Guillaume M, Rodriguez-Vilarrupla A, Gracia-Sancho J, Rosado E, Mancini A, Bosch J, et al. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. J Hepatol 2013;58:240-246.
  • 26
    Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926-931.
  • 27
    Abraldes JG, Graupera M, Zafra C, Rodriguez-Vilarruplaa A, Fernandez M, Garcia-Pagan JC, et al. Simvastatin improves sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. Journal of Hepatology 2005;42:62-63.
  • 28
    Garcia-Caldero H, Rodriguez-Vilarrupla A, Gracia-Sancho J, Divi M, Lavina B, Bosch J, et al. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol 2010;54:660-665.
  • 29
    Rodriguez-Vilarrupla A, Graupera M, Matei V, Bataller R, Abraldes JG, Bosch J, et al. Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis. Liver Int 2008;28:566-573.
  • 30
    Yokoyama Y, Xu H, Kresge N, Keller S, Sarmadi AH, Baveja R, et al. Role of Thromboxane A2 in Early BDL-induced Portal Hypertension. Am J Physiol Gastrointest Liver Physiol 2003;284:G453-60.
  • 31
    Steib CJ, Gerbes AL, Bystron M, op dW, Hartl J, Roggel F, et al. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol 2007;47:228-238.
  • 32
    Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007;132:709-719.
  • 33
    Bruix J, Bosch J, Kravetz D, Mastai R, Rodes J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430-435.
  • 34
    Lopez-Parra M, Claria J, Planaguma A, Titos E, Masferrer JL, Woerner BM, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002;135:891-900.
  • 35
    Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979;77:215-222.
  • 36
    Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011;377:2013-2022.
  • 37
    Fiessinger JN, Bounameaux H, Cairols MA, Clement DL, Coccheri S, Fletcher JP, et al. Thromboxane antagonism with terutroban in peripheral arterial disease: the TAIPAD study. J Thromb Haemost 2010;8:2369-2376.
  • 38
    Song P, Zhang M, Wang S, Xu J, Choi HC, Zou MH. Thromboxane A2 receptor activates a Rho-associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling. J Biol Chem 2009;284:17120-17128.
  • 39
    Laleman W, Van LL, Severi T, Vander E, I, Zeegers M, Bisschops R, et al. Both Ca2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol 2007;292:G556-G564.
  • 40
    Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-1305.
  • 41
    Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012;57:1220-1227
  • 42
    Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.